Adenosine receptor subtypes in the brainstem mediate distinct cardiovascular response patterns.

作者: R.A. Barraco , M.R. El-Ridi , E. Ergene , J.W. Phillis

DOI: 10.1016/0361-9230(91)90192-M

关键词: AdenosineReceptor antagonistEndocrinologyAdenosine A1 receptorAgonistAdenosine receptorCGS-21680Solitary nucleusInternal medicineReceptorBiology

摘要: A limited occipital craniotomy was conducted on urethane-chloralose anesthetized, spontaneously breathing rats to expose the caudal medulla in region of obex. Microinjections highly selective agonists for adenosine receptor subtypes were made into medial nucleus tractus solitarius (NTS) at level posterior portion area postrema. Cardiorespiratory parameters subsequently recorded a 60-min test period following microinjection drug or vehicle solutions. The used: A1 agonist, N6-cyclopentyladenosine (CPA), which is 480-fold receptors rat brain binding assays, and A2 2-p-(2-carboxyethyl)phenethylamino-5'-N-ethylcarboxamidoadenosine (CGS 21680), 170-fold studies over 1500-fold functional assays. results showed that distinct converse cardiovascular response patterns elicited by these microinjections NTS. Specifically, CGS 21680 selectively potent dose-related decreases mean arterial blood pressure (ED50 = 0.064 nmol/kg) pulse (ED50= 0.058 nmol/kg). Conversely, CPA increases 0.62 0.70 Additionally, overall agonist-mediated dramatically different wherein agonist exhibited considerably more rapid time course eliciting its hypotensive responses whereas delayed substantially longer exert hypertensive responses. further shown be receptor-selective since depressor 21680, pressor CPA, completely blocked, respectively, antagonist, 15943A, DPCPX. Taken together, findings provide persuasive vivo evidence showing pharmacologic activation NTS elicits specific with opposite actions cardiorespiratory behavior. These data also indicate separate physiologic are specifically mediated intact nervous system thereby lend additional support case using models assess role function.

参考文章(72)
R. F. Bruns, G. H. Lu, T. A. Pugsley, Adenosine Receptor Subtypes: Binding Studies Topics and Perspectives in Adenosine Research. pp. 59- 73 ,(1987) , 10.1007/978-3-642-45619-0_6
F. L. Eldridge, D. E. Millhorn, Role of Adenosine in the Regulation of Breathing Topics and Perspectives in Adenosine Research. pp. 586- 596 ,(1987) , 10.1007/978-3-642-45619-0_50
D. Jordan, K.M. Spyer, Brainstem integration of cardiovascular and pulmonary afferent activity Progress in Brain Research. ,vol. 67, pp. 295- 314 ,(1986) , 10.1016/S0079-6123(08)62769-7
Jerome H. Chin, Robert J. Delorenzo, A new class of adenosine receptors in brain: Characterization by 2-chloro[3H]adenosine binding Biochemical Pharmacology. ,vol. 35, pp. 847- 856 ,(1986) , 10.1016/0006-2952(86)90254-6
JC Bisserbe, J Patel, PJ Marangos, Autoradiographic localization of adenosine uptake sites in rat brain using [3H]nitrobenzylthioinosine. The Journal of Neuroscience. ,vol. 5, pp. 544- 550 ,(1985) , 10.1523/JNEUROSCI.05-02-00544.1985
N R Zahniser, T V Dunwiddie, C R Lupica, W A Cass, Effects of the selective adenosine A2 receptor agonist CGS 21680 on in vitro electrophysiology, cAMP formation and dopamine release in rat hippocampus and striatum. Journal of Pharmacology and Experimental Therapeutics. ,vol. 252, pp. 1134- 1141 ,(1990)
M. F. Hopkins, M. Williams, D. T. Cote, Geetha Ghai, F. R. Goodman, R. A. Dotson, J. E. Francis, M. B. Zimmerman, Pharmacological characterization of CGS 15943A: a novel nonxanthine adenosine antagonist. Journal of Pharmacology and Experimental Therapeutics. ,vol. 242, pp. 784- 790 ,(1987)
H H Oei, A J Hutchison, R L Webb, M B Zimmerman, G R Ghai, M Williams, CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. Journal of Pharmacology and Experimental Therapeutics. ,vol. 251, pp. 47- 55 ,(1989)
A. J. Hutchison, M. A. Sills, R. Schulz, M. F. Jarvis, M. Williams, Un Hoi Do, [3H]CGS 21680, a selective A2 adenosine receptor agonist directly labels A2 receptors in rat brain. Journal of Pharmacology and Experimental Therapeutics. ,vol. 251, pp. 888- 893 ,(1989)